CME Group Inc. (NASDAQ:CME) HOLD
An elite, near-monopoly exchange fairly priced — a quality compounder to own on weakness, one 200-day reclaim from a BUY, not a chase here.
CME Group runs the world's largest derivatives marketplace — the venue where futures and options on rates, equity indices, energy, agriculture, FX and metals are traded and cleared. It charges a small fee on every contract and guarantees settlement through its clearing house: a toll booth on the plumbing of global finance. This report re-presents the 7 August 2026 Donatien analysis at $264.32 a share — HOLD across all three horizons.
A near-monopoly, capital-light compounder
Business quality scores 82. Once liquidity and open interest pool on one venue, traders cannot easily leave — the offsetting position, the margin efficiency and the clearing all live there, a self-reinforcing network. That gives CME a near-monopoly in its core rate and equity-index complexes, roughly 65% operating margins and almost no capital spending, so nearly all the cash comes back to shareholders. It is valued like a quality compounder on earnings, not like a bank on book value. The catch is simple: quality this obvious rarely stays cheap.
Quality score 82 of 100 · Operating margin ~65%, EBITDA margin ~79%
Fair, not cheap
For a capital-light exchange the right lens is the price-to-earnings multiple, not book value — tangible book is actually negative. On the disciplined anchor, a forward multiple near 20.4 times against a warranted 18.6 times reads 1.10 times: Fair. That is roughly ten percent above the model's fair value, so there is no margin of safety, but it is not expensive either, and CME trades at a slight discount to exchange peers. The regular dividend of $1.30 a quarter was maintained — the raise came back in February — and a variable year-end special dividend takes the all-in cash return to about 4.3%.
Valuation score 53 — Fair band · Warranted P/E ~18.6x vs forward ~20.4x
A recovery the tape has not confirmed
Timing scores 53. CME carved a V-low near $218 in late June and has recovered about 21%, reclaiming its 50-day — the daily frame has turned from a strong downtrend to recovering. But the breakout came on below-average volume, price is still under a declining 200-day at $278.5, and the weekly frame is an outright downtrend. That is recovering, not confirmed, so no entry group is met and the call is Wait. A daily reclaim of the 200-day on volume, or a pullback into the mid-240s, would move timing to improving and flip the medium and long horizons from HOLD to BUY.
Timing score 53 — Neutral · 200-day at $278.5; entry = Wait
What could go wrong
Volume-cyclical: revenue falls when volatility and ADV fade. Rate cuts would trim float income on member collateral. FMX is attacking the Treasury-futures margin-offset moat. Base case is only ~+5%; reward-to-risk is thin here.
Risk vs Reward
Against the current US$264.32, the report frames a bull case at US$315 (+19%), a base case at US$278 (+5%) and a bear case at US$228 (-14%). See the full report for the probability weight behind each path.
The verdict
An elite, near-monopoly exchange fairly priced — a quality compounder to own on weakness, one 200-day reclaim from a BUY, not a chase here.
Read the full report on donatien.ca →
